Plenty of news out of the big ASCO meeting in Chicago this weekend and we've selected a few stories to highlight below. Go here for more ASCO-related press releases than you can shake a stick at.
- ImClone's Erbitux demonstrates good results as first-line therapy for certain lung and colorectal cancers--but good enough to take market share from Genentech's Avastin? Probably not, docs tell the New York Times.
- Two targeted cancer therapies aren't necessarily better than one--in fact, combinations can lessen time-to-disease-progression, the WSJ's Health Blog reports from Chicago. (Lots of great posts from ASCO over at the WSJHB.)
- Infinity's Hsp90 inhibitor IPI-504 (partnered with AstraZeneca) will move into Phase III trials, the company said on Saturday, after data from a Phase I trial of the drug in patients with gastrointestinal stromal tumors confirmed previously seen safety and efficacy trends. The study in refractory GIST patients will begin in the third quarter of 2008. The Pink Sheet Daily has the news.